Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer's SCD drug fails ph. 3 study in latest blow to GBT legacy
Pfizer’s sickle cell disease drug flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.
James Waldron
Aug 18, 2025 7:31am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
HHS cancels mRNA vaccine development funded by BARDA
Aug 5, 2025 7:20pm
Pfizer's embattled obesity program loses another GLP-1 drug
Aug 5, 2025 8:51am
China biotechs ‘reshaping’ US biopharma: Jefferies report
Jul 14, 2025 2:30pm
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
Jul 11, 2025 10:15am
